<DOC>
	<DOCNO>NCT02802631</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , placebo-controlled , single multiple ascend dose study safety , tolerability , pharmacokinetics Minocin® ( minocycline ) injection healthy adult subject .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Minocin® ( Minocycline ) Injection Healthy Adults</brief_title>
	<detailed_description>The purpose study collect safety , tolerability , PK data ascend dose regimen Minocin® ( minocycline ) Injection . The safety , tolerability , PK data support compound potential clinical candidate Europe allow recommendation dose level use future Phase 2/3 study .</detailed_description>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . A sign informed consent form , ability understand study conduct task require study participation , willingness cooperate task , test , examination require protocol , whether research unit discharge , duration study ; 2 . Male female 18 55 year age inclusive ; 3 . Subject body mass index ( BMI ) &lt; 45 kg/m2 ; 4 . Subject good health base medical history physical examination finding clinically meaningful safety laboratory abnormality ( Haematology , blood chemistry , urinalysis ) 12lead ECG result , assess Principal Investigator ( PI ) ; 5 . Vital sign ( BP , pulse temperature ) measure screening/baseline must within follow range : SBP ≥90 ≤150 mm Hg , DBP ≥45 ≤90 mm Hg ; Heart Rate ≥ 45 ≤90 bpm ( take rest supine position least 5 minute ) ; 6 . Expectation intravenous access sufficient allow ease study drug infusion , protocol require blood sample take place ; 7 . Subject commits remain admit research unit course study ; 8 . Female subject surgically sterile , postmenopausal , childbearing potential , agree abstinence use least 2 acceptable method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , barrier method , etc . ) male partner sterilization alone , randomization 7 day completion study . 1 . Subjects know active hepatitis B C , human immunodeficiency virus ( HIV ) infection , know immune deficiency disease screening ; 2 . Blood plasma donation within past 2 month ; 3 . Surgery within 48 hour prior randomization surgery plan study period ; 4 . Females pregnant nursing positive pregnancy test result Screening Visit ; 5 . Males unwilling practice abstinence use acceptable method birth control entire study period ( i.e. , condom spermicide , locally available ) ; 6 . Presence know raise intracranial pressure ; 7 . Use isotretinoin ; 8 . History significant hypersensitivity allergic reaction tetracycline antibiotic ; 9 . Receipt investigational medication investigational device last 30 day prior randomization ; 10 . Treatment prescription OTC drug , within 2 week five halflives , whichever longer , herbal nutritional supplement within 2 week screen , exception acetaminophen/paracetamol minor headache . Subjects allow receive medication duration study ( except abovementioned acetaminophen/paracetamol ) . Birth control hormone replacement also permit long take stable dose least three month Screening Visit remain stable duration study ; 11 . A correct QT ( Fridericia ) ( QTcF ) &gt; 480 msec .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bacterial infection</keyword>
</DOC>